← All drugs
Drug · FAERS side-effect profile with label screen

Albuterol side effects: what 119,292 FDA adverse event reports show

Albuterol · 1,201 reaction terms · 609,744 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

119,292 reports · 68% serious · 10,013 with death outcome · 64% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

FDA label, Indications and Usage

What it is

Albuterol is a member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom.

PubChem CID 2083 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Likely indication confounding 8Reporting / coding artifact 5Lab value / disease marker 6Not in label — unassessed 21
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,161 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Appendicolith227264.4
215.0–325.3ROR 264.9 · calibrated p 5e-11 ✓
104.1 EB05 93.2 · IC025 +6.2
3/3 methods agree
Not in label — unassessedserious n=227 · ♀ 0% (drug 64%) · 100% clinicianno trial arm names this drug
Congenital hiatus hernia106161.7
124.1–210.8ROR 161.9 · calibrated p 4e-9 ✓
82.7 EB05 70.3 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=106 · ♀ 0% (drug 64%) · 100% clinicianno trial arm names this drug
Spirometry abnormal273153.3
130.3–180.4ROR 153.7 · calibrated p 5e-9 ✓
81.2 EB05 73.4 · IC025 +6.0
3/3 methods agree
Lab value / disease markerserious n=270 · ♀ 0% (drug 64%)no trial arm names this drug
Total lung capacity abnormal164133.4
108.8–163.5ROR 133.6 · calibrated p 2e-8 ✓
75.0 EB05 65.8 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious n=161 · ♀ 0% (drug 64%) · 100% clinicianno trial arm names this drug
Total lung capacity increased114126.0
99.0–160.4ROR 126.1 · calibrated p 3e-8 ✓
72.4 EB05 61.9 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=114 · ♀ 100% (drug 64%) · 100% clinicianno trial arm names this drug
Pulmonary vasculitis218123.6
103.9–147.1ROR 123.9 · calibrated p 3e-8 ✓
72.0 EB05 64.3 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious n=218 · ♀ 0% (drug 64%)no trial arm names this drug
Mite allergy257118.8
101.4–139.2ROR 119.0 · calibrated p 4e-8 ✓
70.4 EB05 63.5 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=255 · ♀ 0% (drug 64%)no trial arm names this drug
Analgesic therapy10895.5
75.5–120.8ROR 95.6 · calibrated p 2e-7 ✓
61.2 EB05 52.1 · IC025 +5.3
3/3 methods agree
Reporting / coding artifactserious n=108 · ♀ 0% (drug 64%) · 100% clinicianno trial arm names this drug
Drug therapy11092.1
73.0–116.0ROR 92.1 · calibrated p 3e-7 ✓
59.8 EB05 51.0 · IC025 +5.3
3/3 methods agree
Reporting / coding artifactserious n=110 · ♀ 0% (drug 64%) · 100% clinicianno trial arm names this drug
Reversible airways obstruction17288.3
73.4–106.1ROR 88.4 · calibrated p 3e-7 ✓
58.4 EB05 51.4 · IC025 +5.4
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=172no trial arm names this drug
Dust allergy30079.3
69.2–90.9ROR 79.5 · calibrated p 7e-7 ✓
54.5 EB05 49.5 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=299 · ♀ 0% (drug 64%)no trial arm names this drug
Mycotic allergy26279.2
68.5–91.7ROR 79.4 · calibrated p 7e-7 ✓
54.4 EB05 49.1 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=261 · ♀ 0% (drug 64%)no trial arm names this drug
Ejection fraction17876.9
64.5–91.8ROR 77.0 · calibrated p 9e-7 ✓
53.2 EB05 47.0 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=178 · ♀ 100% (drug 64%)no trial arm names this drug
Asthma-chronic obstructive pulmonary disease overlap syndrome15473.8
61.1–89.1ROR 73.8 · calibrated p 1e-6 ✓
51.6 EB05 45.2 · IC025 +5.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=152 · 100% clinicianno trial arm names this drug
Sensitisation22472.6
62.1–84.9ROR 72.7 · calibrated p 1e-6 ✓
51.2 EB05 45.8 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=224 · ♀ 100% (drug 64%)no trial arm names this drug
Bronchopulmonary aspergillosis allergic26772.2
62.6–83.2ROR 72.3 · calibrated p 1e-6 ✓
51.0 EB05 46.1 · IC025 +5.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=266no trial arm names this drug
Bronchial wall thickening17756.6
47.8–67.1ROR 56.7 · calibrated p 7e-6 ✓
42.7 EB05 37.7 · IC025 +5.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=177no trial arm names this drug
Multiple drug therapy16253.0
44.4–63.2ROR 53.1 · calibrated p 1e-5 ✓
40.6 EB05 35.6 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=160 · ♀ 100% (drug 64%) · 100% clinicianno trial arm names this drug
Bronchial secretion retention28851.7
45.3–59.0ROR 51.8 · calibrated p 1e-5 ✓
39.9 EB05 36.2 · IC025 +5.0
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=281no trial arm names this drug
Pulmonary function test abnormal31844.8
39.6–50.7ROR 44.9 · calibrated p 3e-5 ✓
35.7 EB05 32.5 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=309no trial arm names this drug
Antineutrophil cytoplasmic antibody positive14443.2
36.0–51.8ROR 43.2 · calibrated p 4e-5 ✓
34.6 EB05 30.1 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=144 · ♀ 0% (drug 64%) · 100% clinicianno trial arm names this drug
Full blood count abnormal2,07643.0
41.0–45.1ROR 43.7 · calibrated p 3e-5 ✓
34.6 EB05 33.4 · IC025 +5.0
3/3 methods agree
Lab value / disease markerserious PRR 38.7no trial arm names this drug
Conjunctivitis allergic28843.0
37.8–48.9ROR 43.1 · calibrated p 4e-5 ✓
34.5 EB05 31.3 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=285 · ♀ 0% (drug 64%)no trial arm names this drug
Eosinophilic granulomatosis with polyangiitis33134.3
30.5–38.6ROR 34.4 · calibrated p 1e-4 ✓
28.8 EB05 26.3 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=331 · ♀ 0% (drug 64%)no trial arm names this drug
Polycystic ovaries25734.2
30.0–39.1ROR 34.3 · calibrated p 1e-4 ✓
28.7 EB05 25.9 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=256 · ♀ 100% (drug 64%)no trial arm names this drug
Rhinitis allergic70332.9
30.4–35.7ROR 33.1 · calibrated p 2e-4 ✓
27.8 EB05 26.1 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=680 · ♀ 89% (drug 64%)no trial arm names this drug
Inhalation therapy9932.1
25.9–39.8ROR 32.2 · calibrated p 2e-4 ✓
27.1 EB05 22.9 · IC025 +4.3
3/3 methods agree
Reporting / coding artifact100% consumerno trial arm names this drug
Obstructive airways disorder1,68231.1
29.5–32.7ROR 31.5 · calibrated p 2e-4 ✓
26.5 EB05 25.4 · IC025 +4.6
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
age-adj. PRR 29.1 · serious PRR 23.2no trial arm names this drug
Neuritis22930.6
26.6–35.2ROR 30.7 · calibrated p 2e-4 ✓
26.1 EB05 23.4 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=227 · ♀ 0% (drug 64%)no trial arm names this drug
Temperature regulation disorder31129.0
25.8–32.7ROR 29.1 · calibrated p 3e-4 ✓
25.0 EB05 22.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=309 · ♀ 100% (drug 64%)no trial arm names this drug
Respiratory symptom39428.7
25.8–31.9ROR 28.7 · calibrated p 3e-4 ✓
24.7 EB05 22.7 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=388 · ♀ 21% (drug 64%)no trial arm names this drug
Lupus vulgaris16127.4
23.2–32.3ROR 27.4 · calibrated p 5e-4 ✓
23.7 EB05 20.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=161 · ♀ 100% (drug 64%) · 100% clinicianno trial arm names this drug
Total lung capacity decreased20525.7
22.2–29.7ROR 25.7 · calibrated p 6e-4 ✓
22.4 EB05 20.0 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=189no trial arm names this drug
Sleep disorder due to a general medical condition2,01224.9
23.7–26.1ROR 25.3 · calibrated p 6e-4 ✓
21.9 EB05 21.1 · IC025 +4.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 24.3 · serious PRR 34.7no trial arm names this drug
Obstructive sleep apnoea syndrome17224.6
21.0–28.8ROR 24.6 · calibrated p 8e-4 ✓
21.6 EB05 19.0 · IC025 +4.1
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=170no trial arm names this drug
Chest x-ray abnormal37724.2
21.8–27.0ROR 24.3 · calibrated p 8e-4 ✓
21.4 EB05 19.6 · IC025 +4.2
3/3 methods agree
Lab value / disease markerserious n=376no trial arm names this drug
Increased bronchial secretion30924.0
21.3–27.0ROR 24.0 · calibrated p 9e-4 ✓
21.1 EB05 19.2 · IC025 +4.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=291 · 100% consumerno trial arm names this drug
Forced expiratory volume decreased34123.9
21.4–26.8ROR 24.0 · calibrated p 9e-4 ✓
21.1 EB05 19.3 · IC025 +4.2
3/3 methods agree
Lab value / disease markerserious n=334 · ♀ 34% (drug 64%)no trial arm names this drug
Sputum culture positive9923.9
19.3–29.5ROR 23.9 · calibrated p 1e-3 ✓
21.0 EB05 17.8 · IC025 +3.9
3/3 methods agree
Lab value / disease markerserious n=99 · ♀ 100% (drug 64%) · 100% clinicianno trial arm names this drug
Nasal polyps57823.8
21.8–26.0ROR 23.9 · calibrated p 9e-4 ✓
21.0 EB05 19.6 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=562no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Interstitial lung disease1,4852.72.6–2.9signal
Serious infection11,3592.62.6–2.7signal
Hyponatraemia1,1482.52.4–2.7signal
Venous thromboembolism3,0342.52.4–2.6signal
Depression3,8202.42.3–2.5signal
Heart failure2,3122.32.2–2.4signal
Arrhythmia / qt2,4952.32.2–2.4signal
Anaphylaxis / angioedema1,5622.22.1–2.3signal
Gi bleeding2,1372.12.0–2.2raised
Kidney injury4,9891.91.9–2.0raised
Tendon disorder3951.81.7–2.0raised
Fall / fracture3,8051.81.7–1.8raised
Anaemia2,9071.71.6–1.8raised
Pancreatitis7581.71.5–1.8raised
Hyperglycaemia / diabetes3,1531.61.6–1.7raised
Myocardial infarction1,8491.61.5–1.7raised

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Albuterol (searched ALBUTEROL).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Dyspnoea (shortness of breath)16,6185.3
5.2–5.4ROR 6.0 · calibrated p 0.151
5.2 EB05 5.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.6 · serious PRR 4.5no trial arm names this drug
Asthma9,65816.5
16.2–16.8ROR 17.9 · calibrated p 0.003 ✓
15.1 EB05 14.9 · IC025 +3.9
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 16.7 · serious PRR 15.3no trial arm names this drug
Drug ineffective (drug did not work)9,2541.2
1.2–1.3ROR 1.3 · calibrated p 0.478
1.2 EB05 1.2 · IC025 +0.3Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.6no trial arm names this drug
Cough7,6714.9
4.8–5.0ROR 5.2 · calibrated p 0.214
4.8 EB05 4.7 · IC025 +2.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.5 · serious PRR 5.3no trial arm names this drug
Pneumonia (lung infection)7,2524.0
3.9–4.1ROR 4.2 · calibrated p 0.341
3.9 EB05 3.9 · IC025 +1.9
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.5 · serious PRR 3.4no trial arm names this drug
Nausea7,0741.6
1.5–1.6ROR 1.6 · calibrated p 0.717
1.6 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.8no trial arm names this drug
Fatigue (tiredness)7,0051.6
1.6–1.6ROR 1.6 · calibrated p 0.723
1.6 EB05 1.6 · IC025 +0.6Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.8no trial arm names this drug
Headache6,8271.9
1.9–2.0ROR 2.0 · calibrated p 0.934
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.8 · serious PRR 2.4no trial arm names this drug
Off label use (used outside approved label)6,3451.3
1.3–1.3ROR 1.3 · calibrated p 0.510
1.3 EB05 1.3 · IC025 +0.3Reporting / coding artifactage-adj. PRR 1.2 · serious PRR 1.4no trial arm names this drug
Pain6,1001.7
1.7–1.8ROR 1.8 · calibrated p 0.824
1.7 EB05 1.7 · IC025 +0.8Not in label — unassessedage-adj. PRR 2.0 · serious PRR 1.9no trial arm names this drug
Wheezing5,49317.9
17.4–18.4ROR 18.7 · calibrated p 0.003 ✓
16.3 EB05 16.0 · IC025 +4.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 17.3 · serious PRR 16.2no trial arm names this drug
Diarrhoea (diarrhea)5,2871.4
1.4–1.5ROR 1.5 · calibrated p 0.621
1.4 EB05 1.4 · IC025 +0.5Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.6no trial arm names this drug
Vomiting4,8451.8
1.8–1.9ROR 1.9 · calibrated p 0.865
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 1.9no trial arm names this drug
Dizziness4,7471.7
1.6–1.7ROR 1.7 · calibrated p 0.776
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Anxiety4,3862.7
2.6–2.8ROR 2.8 · calibrated p 0.697
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.9 · serious PRR 2.9no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Albuterol?

In FDA FAERS, the most frequently co-reported reaction terms for Albuterol are dyspnoea, asthma, cough, pneumonia, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Albuterol have an FDA boxed warning?

No. The FDA label retrieved for Albuterol has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Albuterol causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.